Lyell Immunopharma, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Lyell Immunopharma, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2021 to Q2 2024.
  • Lyell Immunopharma, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $5.72M, a 184% increase year-over-year.
  • Lyell Immunopharma, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $15.4M, a 8357% increase year-over-year.
  • Lyell Immunopharma, Inc. annual Nonoperating Income (Expense) for 2023 was $12.4M, a 214% increase from 2022.
  • Lyell Immunopharma, Inc. annual Nonoperating Income (Expense) for 2022 was $3.94M.
  • Lyell Immunopharma, Inc. annual Nonoperating Income (Expense) for 2021 was -$35.4M, a 575% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $15.4M $5.72M +$3.7M +184% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $11.7M -$5.09M -$689K -15.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $12.4M $6.58M +$191K +2.99% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $12.2M $8.19M +$12M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $182K $2.02M +$1.08M +115% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$895K -$4.4M -$4.84M -1119% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $3.94M $6.39M +$42.6M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$38.6M -$3.82M -$4.1M -1435% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$34.5M $938K +$826K +738% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$35.3M $432K +$105K +32.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$35.4M -$36.2M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $286K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $112K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $327K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.